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SUMMARY
Hematopoietic transcription factors are involved in chromosomal translocations, which generate
fusion proteins contributing to leukemia pathogenesis. Analysis of patient’s primary leukemia blasts
revealed that those carrying the t(8;21) generating AML1/ETO, the most common acute myeloid
leukemia-associated fusion protein, display low levels of a microRNA-223 (miR-223), a regulator of
myelopoiesis. Here, we show that miR-223 is a direct transcriptional target of AML1/ETO. By recruit-
ing chromatin remodeling enzymes at an AML1-binding site on the pre-miR-223 gene, AML1/ETO
induces heterochromatic silencing of miR-223. Ectopic miR-223 expression, RNAi against AML1/
ETO, or demethylating treatment enhances miR-223 levels and restores cell differentiation. Here,
we identify an additional action for a leukemia fusion protein linking the epigenetic silencing of a
microRNA locus to the differentiation block of leukemia.INTRODUCTION
Hematopoietic stem cell self-renewal and differentiation
along different lineages is defined by a dynamic interplay
between lineage-specific transcriptional and posttran-
scriptional regulators, including microRNAs (miRNAs),
whose key role in hematopoiesis is recently emerging
(Tenen, 2003; Chen and Lodish, 2005). Epigenetic mech-
anisms such as DNA methylation and posttranslational
modifications of nucleosomal histone proteins contribute
to the correct modulation of gene expression and to the
maintenance of tissue- and cell-type-specific functionsCan(Jaenisch and Bird, 2003; Grewal and Moazed, 2003;
Klose and Bird, 2006; Mikkelsen et al., 2007). Deregulation
of epigenetic mechanisms cooperates with genetic alter-
ations to the establishment and progression of cancer
(Jones and Baylin, 2007; Tenen, 2003).
MiRNAs are a newclass of evolutionary conserved small
RNAs affecting gene expression at the posttranscriptional
level by blocking translation or degrading target messen-
ger RNAs (mRNAs) (Bartell, 2004; Ambros, 2004; Chen
et al., 2004). Their expression is highly regulated according
to the cell’s developmental lineage and shows restricted
expression profiles in adult tissues, including in theSIGNIFICANCE
AML1/ETO is the fusion product of the t(8;21), the most frequent chromosomal translocation in acute myeloid leu-
kemia. We show that the expression of AML1/ETO triggers heterochromatic silencing of genomic regions gener-
ating a microRNA, the miR-223, whose activity is linked to the differentiation fate of myeloid precursors. Overall,
our study identifies miR-223 as an additional pathogenic target for a leukemia fusion protein and provides evi-
dence that links the epigenetic silencing of a microRNA locus to the differentiation block of myeloid precursors.
Suppression of a miRNA gene expands the oncogenic activity of the fusion protein, since miRNA represses the
expression of multiple target proteins. Thus, repression of miRNA expression may represent a key event in the dif-
ferentiation block underlying leukemogenesis.cer Cell 12, 457–466, November 2007 ª2007 Elsevier Inc. 457
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2005; Zhao et al., 2005; Bartell, 2004; Chen et al., 2006;
Fazi et al., 2005). MiRNAs have been found to participate
in regulatory circuits that control development of skeletal
and cardiac muscle and lineage-differentiation fate of he-
matopoietic cells (Fazi et al., 2005; Zhao et al., 2005;
Chen et al., 2006). However, little information is currently
available on factors that modulate miRNA transcription
and expression at the basal or tissue-specific level (Kim
and Nam, 2006).
Developmental programs of normal hematopoiesis are
altered in acute myeloid leukemias (AMLs), which repre-
sents the clonal expansion of hematopoietic precursors
blocked at different stages of erythroid, granulocytic,
monocytic, or megakaryocytic differentiation (Tenen,
2003). Hematopoietic transcription factors and miRNAs
have been found mutated or consistently altered by chro-
mosomal translocations associated to leukemias; their
role in the pathogenesis of these malignancies has been
proposed (Chen, 2005; Hammond, 2006; Calin and Croce,
2006; Saito et al., 2006; Tenen, 2003).
Our previous findings showed a crucial role for the tran-
scriptional activation of miR-223 expression in human
myelopoiesis (Fazi et al., 2005). Here, we investigated
whether deregulated miR-223 expression could be asso-
ciated with the differentiation block underlying the patho-
genesis of distinct leukemia subtypes.
RESULTS AND DISCUSSION
MiR-223 Expression Is Downregulated in AML1/
ETO-Positive Primary Blasts and Cell Lines
The expression levels of miR-223 were quantified in hu-
man hematopoietic cells isolated from healthy donors
and from diagnostic samples of 31 leukemia patients
whose morphological and genetic features are shown in
Table 1. Figure 1A shows that miR-223 is expressed at
high levels in total nucleated cells from peripheral blood
(PB) and bone marrow (BM) from healthy donors, respec-
tively, consisting of mature granulocytes (50%–70%)
and committed/mature myeloid precursors. MiR-223
was detected at the lowest levels of expression in imma-
ture CD34+-hematopoietic stem/progenitor cells isolated
from either normal PB, BM, or cord blood (CB) in leuke-
mias related to the erythroblastic (M6) or lymphoid line-
ages and in the 6 AMLs presenting the most immature
myeloid phenotype (M0 and M1, by FAB classification)
(Bennett et al., 1985). Intermediate levels of miR-223
were measurable in primary samples expressing the
more mature AML phenotypes (acute-promyelocytic
(M3), -myelomonocytic (M4), and -monoblastic (M5) leu-
kemias), and in chronic myeloid leukemia in blast crisis
(CML-BC) (Figure 1A). Overall, these results confirmed
the induction of miR-223 during myeloid differentiation
(Fazi et al., 2005) and related its expression levels to the
stage of maturation block underlying myeloid leukemia
subtypes. However, among the myeloblastic AML-M2
subtype, miR-223 is expressed at high levels in 3/8 de
novo cases and at low levels in 4/4 cases harboring the458 Cancer Cell 12, 457–466, November 2007 ª2007 ElsevierTable 1. Morphological and Genetic Features of
Primary Leukemia Samples
Patient
No.
Morphology
by FAB Karyotype
1 AML/M0 46,XY,der(12)t(12;?)(q23;?)/
46,XY
2 AML/M0 Complex aberrationsa
3 MDS-AML/M1 46,XY,del(7)(q31)
4 AML/M1 47,XX,+11
5 MDS-AML/M1 not available
6 MDS-AML/M1 46,XY,t(3;7;10)(q27;p?;p?),
del(7)q31
7 AML/M2 not available
8 AML/M2 47,XX,add(12)(q23),+mar
9 AML/M2 46,XX
10 AML/M2 not available
11 AML/M2 46,XX,t(8;21)(q22;q22)/47,
idem,+15
12 AML/M2 46,XY,t(8;21)(q22;q22)
13 AML/M2 46,XX,t(8;21)(q22;q22)
14 AML/M2 46,XY,t(8;21)(q22;q22)
15 AML/M3 46,XY,t(15;17)(q22;q21)
16 AML/M3 46,XY,t(15;17)(q22;q21)
17 AML/M3 46,XY,t(11;17)(q23;q21)
18 AML/M3 46,XY,t(15;17)(q22;q21)
19 AML/M4eo 46,XY
20 AML/M4 46,XY,t(4;16)(q25;q22)
21 AML/M4 not available
22 AML/M4 not available
23 AML/M4-M5 not available
24 AML/M5 not available
25 AML/M5a 45,XY,del(7),16
26 AML/M6 46,XY
27 AML/M6 not available
28 CML blast crisis 45,XX,7,t(9;22)(q34;q11)
29 leukemic mantle
cell lymphoma
46,XY
30 ALL 46,XY,del(12)(p13;pter)/46,XY
31 ALL 46,XX
Leukemias were classified according to FAB classification
(Bennett et al., 1985). MDS, myelodisplastic phase preceding
AML; ALL, acute lymphocytic leukemia. Caseswith no detect-
able aberrations by conventional karyotyping were also nega-
tive for the fusion genes PML/RARa, CBFb/MYH11, DEK/
CAN, BCR/ABL, and MLL rearrangements.
a 45,X,inv(Y)(p11q11),3,del(5)(q15q35),7,der(12),14,de-
l(15)(q24q26),der(17),18,20,+4 mar.Inc.
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ETO fusion product (Figure 1A).
In analogy to primary AML blasts, miR-223 was ex-
pressed at the highest levels in the AML-M2 HL60 cell
line (Dalton et al., 1988), while low levels of miR-223
were measurable in the t(8;21)-AML-M2 cell line SKNO-1
constitutively expressing the AML1/ETO oncoprotein
(Fazi et al., 2007) (Figure 1B). The NB4, U937, or K562
cell lines derived from patients respectively presenting
AML-M3, AML-M5, or a CML-BC expressed miR-223
levels that were lower than HL60 but significantly higher
than in SKNO-1 cells (Figure 1B).
Figure 1. MiR-223 Levels in Human Hematopoietic Cells and
in Leukemias
(A) Relative qRT-PCR quantization of miR-223 level in mononucleated
cells (MNC) and CD34+ hematopoietic progenitors isolated from
healthy donors PB, BM, CB, and from 31 leukemia patients classified
by FAB (Bennett et al., 1985), which relies on blasts morphologic and
cytochemical characteristics (Table 1). L-MCL and ALL are PB blasts
from a leukemic mantle cell lymphoma and two acute lymphocytic
leukemia patients, respectively.
(B and C) Upper panels: Relative quantization of miR-223 expression
levels in the indicated leukemia cell lines. SKNO-1 wild-type cells
(WT), SKNO-1 cells infected with a lentiviral empty vector (Mock),
and SKNO-1 cells infected with a lentiviral vector expressing siRNAs
against the fusion region of the AML1/ETO mRNA (siA/E). U937 cells
stably transfected with an empty vector (Mock), HA-tagged AML1/
ETO (A/E-HA), or the PML/RARa (PR9) cDNAs. The results represent
the average of three independent evaluations ± SD. Lower panels:
Immunoblot analysis for the detection of AML1 and AML1/ETO (A/E)
with an anti-AML1 antibody. The increased molecular weight of the
AML1/ETO product in A/E-HA cells in respect to SKNO-1 cells is due
to the HA-tagged domain of the vector. The PML/RARa and C/EBPa
protein were detected with the anti-RARa and anti-C/EBPa antibodies,
respectively. The level of b-tubulin visualized the equal amount of
protein loading. ZnSO4 treatment (100 mM) was used to increase the
expression of AML1/ETO and PML/RARa products in U937 cells.CanWe next infected SKNO-1 cells with a siRNA lentiviral
construct knocking down the AML1/ETO product
(SKNO-1 siA/E cells). This strongly increased the endoge-
nous levels of miR-223 in respect to those measurable in
SKNO-1-wild-type (WT) or -Mock cells (Figure 1B). More-
over, we ectopically expressed an HA tagged AML1/ETO
cDNA in U937 cells (U937-A/E-HA) in a stable or zinc-in-
ducible manner. In these cells, the expression levels of
miR-223 were strongly reduced relative to U937-Mock
cells (Figures 1B and 1C). No effect on miR-223 expres-
sion was exerted by the expression in U937 cells of
PML/RARa, the AML-M3-associated fusion oncoprotein
(Figure 1C). These results suggested that the AML1/ETO
fusion product specifically triggers the transcriptional
silencing of miR-223.
AML1/ETO Oncoprotein Localizes at an
AML1-Binding Site on the pre-miR-223 Gene
Affecting Its Transcriptional Regulation
AML1/ETO is the fusion product of the t(8;21) transloca-
tion, the most common karyotypic abnormality of AML,
which is detected in about 15% of total cases and in up
to 40% of the FAB AML-M2 subtype. Expression of
AML1/ETO in hematopoietic stem/precursor cells dramat-
ically expands myeloid progenitors in vitro causing pre-
leukemic myeloproliferative disorder in vivo. AML1/ETO
maintains the ability of AML1 to bind the consensus
sequence TGT/cGGT on target gene promoters and acts
as a dominant-negative repressor of AML1 target genes,
including c-fms, GM-CSF, p14ARF, and the retinoic acid
receptor b among others (Linggi et al., 2002; Frank et al.,
1995; Zhang et al., 1994; Fazi et al., 2007; Nimer and
Moore, 2004; Hess and Hug, 2004).
A bioinformatic search showed the presence of a puta-
tive AML1 binding site at the 50 end of the predicted ‘‘core-
promoter’’ sequence on the pre-miR-223 upstream region
(Zhou et al., 2007). By chromatin immunoprecipitation
(ChIP) assay we investigated the in vivo localization of
the AML1/ETO protein constitutively present in SKNO-1
cells or ectopically expressed in U937 cells at the AML1-
binding site on the miR-223 gene. We found that DNA
sequences containing the AML1-binding site are immuno-
precipitated by an a-AML1 antibody (Figures 2A and 2B,
oligo1). Since these myeloid cell lines express the wild-
type AML1, the AML1/ETO occupancy of this chromatin
region was indicated by the detection of ETO immuno-
complexes in SKNO-1 and U937-A/E-HA cells, but not in
U937-Mock cells (Figures 1B and 2B). ChIP analysis per-
formed with an a-HA antibody to distinguish the AML1/
ETO-HA fusion protein, expressed by U937-A/E-HA cells
from the endogenous AML1 or ETO products, confirmed
the presence of AML1/ETO at this AML1 target site. The
specificity of these interactions was indicated by their
absence if distal sequences on miR-223 gene lacking
the AML1-binding sites were amplified in the same sam-
ples (Figures 2A and 2B oligo2). These findings suggested
that the AML1 site on the pre-miR-223 ‘‘core-promoter’’
sequence is a molecular target for the AML1/ETO onco-
protein in vivo.cer Cell 12, 457–466, November 2007 ª2007 Elsevier Inc. 459
Cancer Cell
Heterochromatic Silencing of miR-223 by AML1/ETOFigure 2. The AML1/ETO Oncoprotein Acts on the AML1 DNA-Binding Site on the pre-miR-223 Upstream Sequence
(A) Schematic representation of the AML1 site (nt426 to416) and of the distribution of the CpGdinucleotides (black circles) (nt203 to +137) along
themiR-223 gene. Numbers are the nucleotides relative to the 50 end of the pre-miR-223 (+1). Arrows indicate the location of the primers used in ChiP
assay.
(B) Chromatin was immunoprecipitated using the indicated antibodies or in absence of antibody (no-Ab). PCRwas performed by using oligo1 primers
designed to amplify DNA sequences surrounding the AML1-binding site and the CpGs on pre-miR-223 gene. Oligo2 primers (A) were designed for the
amplification of a distal region onmiR-223 gene lacking the AML1 site to evaluate the specificity of protein binding. Input shows the amplification from
sonicated chromatin. Amplification of GAPDH DNA was a control for nonspecific precipitated sequences.
(C) Human 293T cells were transiently cotransfected for 48 hr with luciferase reporter vectors containing the sequence of the miR-223 regulatory
regions (MRRs showed in [A]), and increasing amounts (10, 50, and 100 ng) of pcDNA3 vectors containing (293T-A/E) or not (293T-Mock) HA-
tagged-AML1/ETO cDNAs.
(D) MMR luciferase reporter vectors were transiently transfected for 48 hr into U937 cells expressing a HA-tagged-AML1/ETO in a stable or zinc-
inducible manner (U937-A/E) or an empty vector (U937-Mock) cells. ZnSO4 treatment (100 mM) was used to increase the expression of AML1/
ETO. The data are expressed as activity relative to that of the empty pGL2-LUC vector alone. A cotransfected Renilla Luciferase vector pRL-SV40
was used as an internal control for normalization of the luciferase activity in each sample. The results shown are the average of three independent
evaluations ± SD.We therefore addressed the transcriptional regulatory
functions of AML1/ETO product on miR-223 expression.
Luciferase reporter constructs containing different por-
tions of the pre-miR-223 regulatory region (MRR) sur-
rounding the AML-1 site (schematically represented in
Figure 2A) were cotransfected with increasing amounts
of expression plasmids encoding for the AML1/ETO prod-
uct (A/E) or for the empty vector (Mock) into 293T cells.
The same MRR reporter vectors were also transfected
into U937-Mock and U937-A/E cells, which have a stable
expression of the AML1/ETO protein that can be further
induced by zinc. In both 293T and U937 cells, the expres-
sion of AML1/ETO caused a dose-dependent decrease in
the activity of the MRR1 and MRR2 constructs, both pre-
senting the putative AML1 site on pre-miR-223, but not of
the MRR3 lacking this binding site.
Notably, the luciferase activity of the MRR1mut and the
MRR2mut vectors, bothmutated in the AML1-binding site
was not modified by AML1/ETO presence (Figures 2C and460 Cancer Cell 12, 457–466, November 2007 ª2007 Elsevier I2D), thus showing the contribution of this site to the
AML1/ETO- dependent silencing of miR-223.
AML1/ETO Triggers the Heterochromatic
Silencing ofmiR-223 Genomic Regions
The oncogenic properties of AML1/ETO are linked to its
ability to form oligomeric complexeswith increased affinity
for histone deacetylase (HDAC) and DNA methyltrans-
ferases (DNMTs) rendering AML1/ETO a potent transcrip-
tional repressor (Liu et al., 2005, 2006; Fazi et al., 2007).
DNMTs methylate the cytosine within CpG dinucleotides
(CpGs), frequently gathered in clusters (‘‘CpG islands’’)
(Jaenisch andBird, 2003; Jones andBaylin, 2007). Methyl-
ated CpGs recruit DNA-methyl CpG-binding proteins
(MeCPs and MBDs). Often, DNMTs, MeCPs, and MBDs
are associated with other chromatin remodeling activities
including HDACs (Jaenisch and Bird, 2003; Jones and
Baylin, 2007; Klose and Bird, 2006). However, it has been
shown that genomic underrepresented and randomlync.
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Heterochromatic Silencing of miR-223 by AML1/ETOFigure 3. Epigenetic Status of miR-223
Gene in AML1/ETO-Positive Cells
(A) Schematic representation of the genomic
structure of human miR-223 gene as reported
by the UCSC Genome Browser website
(http://genome.ucsc.edu/). The location of the
exon sequences (E), the AML1-binding site,
and the CpG dinucleotides (indicted as black
circles along nt 203 to +137 and nt 3760
to 3413) on the miR-223 gene are numbered
relative to the 50 end of the pre-miR-223 (nt +1
to +111).
(B and C) Upper panels: ChIp assays per-
formed in the indicated cell lines using anti-
bodies specific for the acetyl-H4 and acetyl-
H3 forms or (D) for the 5-methylcytosine
(5MetC). PCR amplifications were performed
using oligo1, designed to amplify DNA se-
quences surrounding the AML1-binding site
and the nearby CpGs (described in Figures
2A and 2B), and oligo 3 designed to amplify
the 50 end upstream region of miR-223 gene
(nt 3514 to 3300). Lower panels: Genomic
bisulfite sequencing assay was performed to
detect the methylation status of the three
CpG dinucleotides dispersed along nt 3760
to 3413 (plotted as circles on the left side of
each methylation subpanel) and the six CpG
dinucleotides clusterized along nt 203 to
+137 of miR-223 gene sequence (circles on
the right side of each methylation subpanel). Black circles and empty circles represent methylated and unmethylated CpG dinucleotides, respec-
tively. Cells were also treated or not with 1 mM 5-azacytidine for 40 hr. For each sample, the percentages of global methylation level of these regions
on the miR-223 gene are indicated.distributed CpG dinucleotides can act as hotspots for ab-
errantmethylationandgenesilencing (Santoroet al., 2002).
ChIP analysis revealed the presence of DNMT1,
DNMT3a, DNMT3b, MeCP2, and HDAC1 at the pre-miR-
223 chromatin regions occupied by AML1/ETO in U937-
A/E-HA and SKNO-1 cells, whereas only a faint DNMT3
reactivity was detectable at this site in U937-Mock cells
(Figure 2B). We therefore investigated if the aberrant
recruitment of HDAC1, DNMTs, and MeCP2 activities by
AML1/ETO modifies nucleosomal histone tails and DNA
methylation status on the pre-miR-223 upstream se-
quence (Figure 3A). We performed ChIP analysis using
antibodies recognizing the acetylated forms of histone H3
and H4 and PCR amplification of pre-miR-223 upstream
regions adjacent the AML1 site. At this chromatin region,
H3 and H4 histones are hyperacetylated in HL60 and
U937-Mock cells, while decreased acetylation levels are
measurable in both U937-A/E and SKNO-1 cells (Figures
3B and 3C). The reduced histone acetylation in AML1/
ETO-expressing samples suggested a hindered transcrip-
tion at these chromatin sites on the pre-miR-223 gene
(Klose and Bird, 2006). Moreover, ChiP assay performed
with an a-50-methylcytosine antibody to immunoprecipi-
tate sonicated naked DNA showed that cytosines on the
DNA region near the AML1 site on pre-miR-223 gene are
methylated in both SKNO-1 and A/E-HA cells, but not in
Mock or HL60 cells (Figure 3D). Notably, along a 340 bp
sequence (nt 203 to +137) containing pre-miR-223, six
CpG dinucleotides are all assembled in the upstream,Cabody, and downstream regions of the pre-miR-223 se-
quence at a distance of one or two nucleosomes from
the AML1 site, while only four sparse CpGs were present
within about 1500 bp downstream from this region, as
schematically represented in Figure 2A. Interestingly, ge-
nomic bisulfite sequencing showed a higher frequency of
methylatedCpGdinucleotides encompassing theendoge-
nous pre-miR-223 gene sequences in U937-A/E-HA (60%)
and in SKNO-1 cells (63%) as compared to Mock (8%) or
HL60 (4%) cells, confirming the basal hypermethylated
status of these CpGs in AML1/ETO-positive cells (Figures
3B and 3C). Notably, in U937-siA/E cells in which the
knockdown of AML1/ETO reactivatedmiR-223 expression
(Figure 1B, 4A), histone H3 and H4 were hyperacetylated
and the CpGs methylation level was decreased (40%) at
these sites on pre-miR-223 gene (Figure 3C).
While this paper was in preparation, Fukao et al. (2007)
identified a conserved promoter region located at about
3400 bp relative to the 50 end of the pre-miR-223 (Fig-
ure 3A). The sequence analysis of this region revealed
the presence of three dispersed CpG dinucleotides (Fig-
ure 3A). Bisulfite genomic sequencing demonstrated that
these CpGs are constitutively unmethylated in human my-
eloid cell lines and that their methylation status is not
changed either in the presence or in the absence of the
AML1/ETO fusion protein (Figures 3B and 3C). Accord-
ingly, ChIP analysis showed that the histones H3 and H4
acetylation status at this chromatin site did not change
in relation to AML1/ETO expression (Figures 3B and 3C).ncer Cell 12, 457–466, November 2007 ª2007 Elsevier Inc. 461
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region (Fukao et al., 2007) also lacked a putative AML1-
binding site as revealed by bioinformatic searches per-
formed with the MatInspector Professional and the Trans-
fac softwares. Thus, the chromatin remodeling complex
aberrantly formed by AML1/ETO and the hypermethyla-
tion of the small CpG-cluster present in a close vicinity
to the miR-223 ‘‘core promoter region’’ containing the
AML1-binding site appear to be a keymechanism for tran-
scriptional gene silencing of miR-223. Whether methyla-
tion at this site could be associated to the tissue-specific-
ity ofmiR-223 gene is an interesting question arising from
the recent work from Zhang et al., (2006), which requires
a more in depth investigation in the human hematopoietic
system.
Demethylating Treatment, RNAi against AML1/
ETO, or Ectopic miR-223 Expression Enhances
miR-223 Level and Restores Blasts Differentiation
We next treated the AML1/ETO-positive SKNO-1 cells
with the DNMT inhibitor 5-azacytidine. This demethylating
drug (1) increased by about 2- to 3-fold miR-223 expres-
sion (Figure 4A), (2) decreased both the ability of the a-
50-methylcytosine antibody to immunoprecipitate naked
DNA at chromatin sites surrounding the AML1 site on
pre-miR-223 gene (Figure 4B) and the methylation status
Figure 4. Enhancement of microRNA-223 Levels by siAML1/
ETO and 5-azacytidine Treatment Restores Myeloid Differen-
tiation of SKNO-1 Cells
(A) SKNO-1 cells (WT, Mock, and si-A/E), were treated or not with 1 mM
5-azacytidine (AZA) for 40 hr. MiR-223 relative expression levels were
evaluated by qRT-PCR. Immunoblot analysis was performed using an
anti-NFI-A antibody. The immunodetection of b-tubulin was used as
loading control.
(B) ChIP assay performed with the anti-5-methylcytosine (5MetC) an-
tibody and the oligo1 or primers.
(C) Effect of 40 hr treatment with 5-azacytidine on the percentage of
cells positively stained for CD11b and CD14 surface markers as mea-
sured by FACS analysis. The results represent the average of three
independent evaluations ± SD.462 Cancer Cell 12, 457–466, November 2007 ª2007 Elsevierof endogenous pre-miR-223 CpGs (from 63% to 46% of
5-methylcytosine) (Figure 3C), (3) decreased the accumu-
lation of the NFI-A protein, a recognized target of miR-223
action (Fazi et al., 2005), thus indicating that the demethy-
lating action of 5-azacytidine is able to restore a functional
endogenous mature miR-223 (Figure 4A), and (4) induced
granulocytic maturation of the cells as indicated by the in-
creased expression levels of the myeloid differentiation
marker CD11b, but not of the monocytic marker CD14
(Figure 4C). Interestingly, in si-A/E cells miR-223 re-ex-
pression reduced the protein levels of its target NFI-A
and increased the percentage of cells expressing the my-
eloid differentiation marker CD11b (Figures 4A and 4C).
Treatment of siA/E cells with 5-azacytidine affected either
methylation or phenotypic changes with respect to those
measurable in untreated cells (Figures 4B, 4C, and 3C),
further linking AML1/ETO expression, heterochromatic
transcriptional silencing of miR-223 to the differentiation
block present in t(8;21) AML blasts.
In agreement with this evidence, stable ectopic expres-
sion ofmiR-223 in SKNO-1 cells obtained by infection with
the lenti-223 vector reduced the accumulation of the NFI-
A product and induced granulocytic maturation as mea-
sured by morphology (showing chromatin condensation
with nuclear segmentation, decreased nuclear/cytoplas-
mic ratio, decreased cytosolic basophilia, appearance of
paranuclear Golgi region, and appearance of specific
granules), expression of myeloid surface differentiation
marker CD11b (Figure 5) and by NBT reduction assay
(data not shown).
Figure 5. Ectopic miR-223 Expression Reprograms Myeloid
Differentiation in SKNO-1 and HL60 Myeloid Leukemia Cells
HL60 and SKNO-1 cells were infected with a lentiviral vector express-
ing miR-223 (Lenti-223, hatched bars) or with the empty lentiviral
vector (Vector, white bars).
(A) Changes inmorphology by light-field microscopy ofWright-Giemsa
stained cells (Scale bars, 5 mm).
(B) Relative miR-223 expression levels as evaluated by qRT-PCR.
Immunoblot analysis was performed using an anti-NFI-A antibody.
The immunodetection of b-tubulin was used as loading control.
(C) Percentage of cells positively stained for CD11b and CD14myeloid
surface markers as measured by FACS analysis. The results represent
the average of three independent evaluations ± SD.Inc.
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have a stronger effect in restoring SKNO-1 cell differenti-
ation than ectoptic miR-223 expression, as indicated by
the percentage of CD11b-positive cells (Figure 4C and
5C). This may suggest that the silencing of miR-223 ex-
pression by AML1/ETO only accounts for part of the differ-
entiation block caused by AML1/ETO. Supporting this hy-
pothesis, the expression of the CCAAT/enhancer binding
protein alpha (C/EBPa) product in SKNO-1 siA/E cells is
restored (Figure 1B). C/EBPa is a key transcriptional reg-
ulator of granulocytic differentiation of myeloid precursor
(Radomska et al., 1998), which is indirectly silenced by
AML1/ETO via protein-protein interaction blocking the
positive autoregulatory regulation of C/EBPa own pro-
moter (Pabst et al., 2001).
We recently described the transcriptional activation of
C/EBPa and posttranscriptional regulation of NFI-A by
miR-223 as essential for granulocytic differentiation re-
sponse of acute promyelocytic leukemia blasts to the dif-
ferentiating agent retinoic acid (Fazi et al., 2005). In the
same study, we also reported granulocytic differentiation
Figure 6. Ectopic miR-223 Expression Reprograms Myeloid
Differentiation in Primary Blasts from Acute Myeloid Leuke-
mia Patients
Fresh primary blasts were isolated from the peripheral blood of two
newly diagnosed AML patients (18 and 23 of Table 1), showing an initial
percentage of circulating blasts greater than 95%. Blasts were in-
fected (Lenti-223, hatched bars) with the lentiviral vector expressing
miR-223 or with the empty lentiviral vector (Vector, white bars). After-
wards, cells were cultured for a week and collected for morphological,
immunophenotypic, and miR-223 expression level evaluation. (A)
Changes in morphology by light-field microscopy of Wright-Giemsa
stained cells (scale bars, 5 mm). (B) The values indicate the miR-223
expression level in primary AML blasts ectopically expressing the
Lenti-223 versus that measured in the same blasts infected with the
empty vector as evaluated by qRT-PCR. (C) Ratio of the CD11b
myeloid differentiation antigen expression levels in Lenti-223 primary
AML blasts versus that measured in empty vector infected blasts
by quantitative FACS analysis The results represent the average of
two independent evaluations ± SD.Canin miR-223-transduced acute promyelocytic leukemia pa-
tient-derived NB4 cells carrying the t(15:17) chromosomal
translocation and expressing the PML/RARa fusion prod-
uct (Fazi et al., 2005). Here, we show that, when engi-
neered with the lenti-223 to overexpress the miR-223,
the human myeloblastic HL60 cell line, which do not carry
oncogenic fusion products, also entered a granulocytic
pathway of differentiation (Figure 5).
Moreover, the infection of fresh primary blasts isolated
from the peripheral blood of two consecutive newly diag-
nosed acute myeloid leukemia patients (18 and 23 of
Table 1) with a lentiviral vector expressing miR-223,
increased the expression level of miRNA-223 of about
1.6- to 1.8-fold after a week of culture. This induction re-
sulted in primary blast granulocytic differentiation as
shown by morphology and by the increased expression
(about 2-fold) of the immunophenotypic myeloid differen-
tiation marker CD11b, but not of CD14 (Figure 6 and data
not shown). This indicates that the levels of miR-223 ex-
pression are critical for the development of the granulo-
cytic differentiation program and that titrated miR-223
expression can reprogram myeloid differentiation in dif-
ferent leukemia subtypes independently from the pres-
ence of a specific genetic lesion.
Cancer is a genetic and epigenetic disease (Jones and
Baylin, 2007; Zardo et al., 2002). Compelling evidence
indicates a role for genetic alteration in the initiation and
progression of tumors. The deregulation of epigenetic
mechanisms of gene expression, such as hypermethyla-
tion of promoter and coding sequences, is also a key on-
cogenic mechanism for the inactivation of tumor suppres-
sors in a wide range of tumor types. Heterochromatic
gene silencing can represent an alternative oncogenic
mechanism to gene mutation or deletion for the transcrip-
tional repression of tumor suppressor genes (Zardo et al.,
2002; Baylin and Ohm, 2006; Jones and Baylin, 2007).
Tumor suppressor or oncogenic activities have been re-
cently proposed for miRNAs (Chen, 2005; Hammond,
2006; Calin and Croce, 2006; Saito et al., 2006).
Here, we show that the heterochromatic silent state of
genomic regions generating a miRNA, the miR-223
gene, whose activity is linked to the differentiation fate of
myeloid precursors is triggered by the expression of
AML1/ETO, the oncogenic fusion product of the most fre-
quent chromosomal translocation in AML. AML1/ETO tar-
gets themiR-223 due to its interaction with the AML1 site
at the pre-miR-223 upstream region where it recruits
HDAC and DNMT activities that deacetylate histone pro-
teins and methylate CpGs. Newly methylated CpGs act
as docking sites for the DNA-methyl CpG-binding protein
MeCP2. Through changes in chromatin conformation, the
AML1/ETO-associated complex resets themiR-223 gene
to a repressed ground state contributing to the differenti-
ation block of myeloid precursors (Figure 7). Of note, that
either ectopic miR-223 expression, downregulation of
AML1/ETO protein levels, or the use of demethylating
agents reactivate miR-223 expression and restore mye-
loid differentiation in t(8;21)-AML blasts. Preliminary im-
munophenotypic data obtained on primary blasts fromcer Cell 12, 457–466, November 2007 ª2007 Elsevier Inc. 463
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also supported the ability of either the AML1/ETO knock-
down by siRNAs or the ectopic miR-223 expression to
reprogram primary leukemia cells into a granulocytic path-
way of differentiation (data not shown).
This evidence establishes an important relationship
between aberrant heterochromatic silencing of a tissue
and developmental stage-specific miRNA transcription
and differentiation block of leukemia. Suppression of
a miRNA gene also carries the potential to greatly expand
the fusion protein oncogenic activity since miRNA re-
presses the expression of multiple target proteins.
The relevance of the miR-223 silencing is also high-
lighted by the consequences of its ectopic expression
that alone is sufficient to reprogram the myeloid differenti-
ation program in distinct myeloid leukemia subtypes. This
suggests deregulated miRNA production as a common
pathway required for the differentiation block underlying
myeloid leukemia pathogenesis and reveals miRNAs as
additional molecular targets for therapeutic intervention
in cancer.
EXPERIMENTAL PROCEDURES
Clinical Samples
The study was approved by the local internal review boards and ethic
committees. Written informed consent was obtained from each sub-
ject. Normal mononuclear cells and CD34+ cells were isolated from
the BM, PB, or CB of healthy donors as reported (Fazi et al., 2007). Leu-
kemia blasts were obtained from the BM and/or PB of 31 leukemia
patients. Cases were classified according to the FAB classification
and showed an initial percentage of circulating blasts greater than
60% (Bennett et al., 1985). Blasts isolation and molecular analysis to
detect the AML-associated fusion genes were performed as described
(Fazi et al., 2007).
Cell Lines and Cell Cultures
HL60, NB4, K562, U937, U937-A/E-HA clone 9, U937-PR9, SKNO-1,
and SKNO-1-siA/E-RNA cell lines were maintained in RPMI 1640
Figure 7. SchematicModel for theHeterochromatic Silencing
of miR-223 Gene by AML1/ETO
In myeloid precursors, the occupancy of the AML1-binding site
(TGTGGT) on the pre-miR-223 promoter by AML1 is associated with
a chromatin status permissive for transcription. The AML1/ETO onco-
protein targets this binding site, where it aberrantly recruits HDAC,
DNMT and MeCP2 activities that deacetylate histone proteins and
methylate CpGs. This produces a chromatin packaging nonpermissive
formiR-223 transcription, which contributes to the differentiation block
of AML1/ETO+ myeloid precursors. White and black circles indicate
the unmethylated and methylated CpG dinucleotides, respectively.
Dark gray marks the pre-miR-223 region, while that encoding the
miR-223 mature form is marked in black. Numbers are the nucleotides
relative to the 50 end of the pre-miR-223 (+1).464 Cancer Cell 12, 457–466, November 2007 ª2007 Elsevier Inmedium supplemented with 50 mg/ml streptomycin, 50 IU penicillin,
and 10% FCS as described (Drexler et al., 1999; Grignani et al.,
1993; Fazi et al., 2005, 2007). Primary AML blasts were cultured in
IMDM medium supplemented with 50 mg/ml streptomycin, 50 IU pen-
icillin, and 20% FCS. The lentiviral vector Lenti-223 was used for the
ectopic induction of the miR223 into myeloid cell lines (SKNO-1 and
HL60) and primary blasts to generate the Lenti-223 cells (Fazi et al.,
2005). Cells were infected and purified by fluorescence activated cell
sorting as reported (Fazi et al., 2005). Treatment with 5-azacytidine
(Sigma-Aldrich, Milan, Italy) was performed at a concentration of 1
mM for 40 hr. Human embryonic kidney 293T cells were cultured in
DMEMmedium supplemented with 50 mg/ml streptomycin, 50 IU pen-
icillin, and 10% FCS.
RNA Extraction and Analysis
Total RNAwas extracted from cells using the TRIzol RNA isolation sys-
tem (Invitrogen). The relative quantity of miR-223 was measured on
200 ng of total RNA by qRT-PCR using the mir-Vana Detection Kit
(Ambion, Applied Biosystem, Milan) in the ABI PRISM 7000 Sequence
Detection System (Applied Biosystem), and it was determined by the
comparative CT method using snRNA U6 levels for normalization as
recommended by the manufacturer’s instructions.
Immunoblot Assays
Immunoblot assays were performed on total cell lysates (50 mg) using
the rabbit polyclonal antibodies anti-AML1/RHD (Oncogene Science),
anti-RARa (Santa Cruz Biotechnology, Santa Cruz, CA), anti-NFI-A
(Abcam, Cambidge, UK), or the anti-C/EBPa (Santa Cruz Biotechnol-
ogy). The anti-b-tubulin mouse monoclonal IgG (Sigma-Aldrich) was
used to normalize the amount of the samples analyzed. The immuno-
reactivity was determined by the ECL method (Amersham Biosci-
ences).
Transactivation Assays
DNA fragments from nt 807 (MRR1) or nt 492 (MRR2) or nt 396
(MRR3) to nt +36 relative to the pre-miR-223 were PCR amplified
from human genomic DNA using the forward primers 50-GGGCACTT
TAATAGCTGCCA-30 or 50-GGTTGCCTAACTAGCTAATG-30 or 50-GAA
TTGAGAAGAGGGAGCAA-30, respectively, coupled with the reverse
primer 50-TCAAATACACGGAGCGTGG-30. All the PCR fragments
were inserted in the pGL2-LUC reporter vector (Promega). The MRR1,
MRR2, and MRR3 constructs were used to generate the MRR1-,
MRR2-, and MRR3-mut plasmids in which the 50-TGTGGT-30 direct
motif of the AML1 site was mutated to 50-ACCGGT-30. To generate
the mutations the QuikChange Site-Directed Mutagenesis Kit (Strata-
gene) was used according to manufacturer instructions. Human em-
bryonic kidney 293T cells (2 3 105) were plated in 12-well plates and
transiently cotransfected by the Lipofectamine Reagent method (Invi-
trogen) with 10, 50, or 100 ng of the pcDNA3 vectors containing or not
the HA-tagged-AML1/ETO cDNAs (Fazi et al., 2007), 300 ng of the LUC
reporter constructs described above. U937-Mock and U937-A/E cells
were pretreated or not with 100 mMZnSO4 (16 hr) and then plated (53
105/well) in 24-well plates. Cells were transiently transfected by the Fu-
GENE reagent (Roche, Mannheim, Germany) with 1.5 mg of the LUC re-
porter constructs described above. A cotransfected pRL-SV40 Renilla
Luciferase reporter vector (Promega) was used as an internal control
for normalization of luciferase activity in each sample. Cells were har-
vested 48 hr posttransfection and assayed with Dual Luciferase Assay
(Promega) according to the manufacturer’s instructions.
Chromatin Immunoprecipitation Assay
The addition to cultured cells (23 106) of formaldehyde (1% final con-
centration) for 10 min at 37C was used to crosslink the proteins to
DNA. After sonication, the chromatin was immunoprecipitated over-
night with 5 ml of the following antibodies recognizing AML1/RHD,
ETO (Ab-1) (Oncogene Science), HA monoclonal (Babco, Richmond,
CA), DNMT1 (New England BioLabs, Ipswich, MA), DNMT3a and
DNMT3b (Abcam), HDAC1 (Santa Cruz Biotechnology), MeCP2,c.
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Lake Placid, NY). ChIP using the Cytosine (5-Methyl) (Abcam) antibody
was performed on naked and sonicated DNA extracted from the same
cell samples. A genomic pre-miR-223 upstream gene region close to
the putative AML1-binding site indicated by the MatInspector Profes-
sional (http://www.genomatix.de) and the TransFac software pack-
ages (http://www.gene-regulation.com/pub/programs.html), was am-
plified with the following primer sequences designed by the Primer
Express software (Applied Biosystem): oligo1 (nt400 to186) forward
50-GGGAGAATTGAGAAGAGGGA-30 and oligo1 reverse 50-GATAAG
CAGGTAAAGCCCGA-30. The other pre-miR-223 upstream regions
were amplified with the following primer sequences: oligo2 (nt
2467 to 2272) forward 50-TCTGGGATTTTTAGGCATGG-30 and
oligo2-reverse 50-AAGAGCGTCATCAAGCCACT-30; oligo3 (nt 3514
to 3300) forward 50-GCATCCAGATTTCCGTTGGCTAAC-30 and
oligo3-reverse 50-GGCAAATGGATACCATACCTGTCA-30. PCR for
GAPDH was performed using the conditions and primers already
described (Fazi et al., 2005).
Cell Differentiation
Cell differentiation was evaluated by light microscopy morphological
examination of Wright-Giemsa-stained cytospins; nitroblue tetrazo-
lium (NBT) dye reduction assay (at least 500 morphologically intact
cells per experimental condition were counted and corrected for viabil-
ity, measured by trypan blue exclusionmethod); direct immunofluores-
cence staining of cells using an allophycocyanin (APC)-conjugated
mouse anti-human CD11b antibody; and a peridinin chlorophyll pro-
tein (PerCP)-conjugated mouse anti-human CD14 antibody (Becton
Dickinson, San Jose, CA) as described (Fazi et al., 2005, 2007). A min-
imum of 50,000 events were collected for each sample by a FACScan
flow cytometer (Becton Dickinson) using CellFit software (Becton
Dickinson) for data acquisition and analysis.
Bisulfite Modification and Genomic Sequencing
The methylation status of the CpG dinucleotides within two regions
(nt 203 to +137 and nt 3760 to 3413), relative to the 50 end of
the pre-miR-223 gene, was analyzed. Bisulfite sequencing assay
was performed on 2.5 mg of bisulfite-treated genomic DNA from
HL60, U937 (Mock, A/E-HA), and SKNO-1 (WT, Mock, and siA/E) cell
lines. After bisulfite conversion performed as previously described
(Zardo et al., 2002), the fragments of interest were amplified using
the following specific primer pairs: oligo1 forward 50-AGTTTTTAGT
TGAGTATTGGGTG-30; oligo1 reverse 50-CTTATATCCAACTAACAAT
CCATTC-30; oligo2 forward 50-AATTTGTTTTGTGATATTGAGTATTT
TT-30; oligo2 reverse 50-TACAAAAACCAAATAAAATTAAACTTTC-30.
PCR products were gel purified and cloned into the TOPO TA Clon-
ing/pCR2.1 TOPO kit (Invitrogen). We subjected individual bacterial
colonies to PCR using vector-specific primers (sequences available
upon request), and the products were sequenced for the analyses of
DNA methylation.
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